Identification
- Summary
Aluminum hydroxide is an antacid used for the symptomatic relief of heartburn, acid indigestion, and sour stomach.
- Brand Names
- Acid Gone, Almacone, Derma Gran, Gaviscon, Gaviscon Chewable, Gelusil, Maalox Plus, Mi-acid, Mi-acid Double Strength, Mintox Plus, Mylanta
- Generic Name
- Aluminum hydroxide
- DrugBank Accession Number
- DB06723
- Background
Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Aluminum hydroxide (DB06723)
- Weight
- Average: 78.0036
Monoisotopic: 77.989757403 - Chemical Formula
- AlH3O3
- Synonyms
- Aluminio hidróxido
- Aluminium hydroxide
- Aluminium hydroxide gel, dried
- Aluminium hydroxide, dried
- Aluminum hydroxide
- Aluminum hydroxide gel, dried
- Aluminum hydroxide, dried
- Dried aluminium hydroxide
- Dried aluminum hydroxide gel
- External IDs
- NSC-664400
Pharmacology
- Indication
For relief of heartburn and acid indigestion.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Abdominal pain Combination Product in combination with: Magnesium trisilicate (DB09281), Kaolin (DB01575) ••• ••• •••••• Used in combination to treat Acid reflux Combination Product in combination with: Simethicone (DB09512), Magnesium hydroxide (DB09104) ••• ••• ••••••• •••••••• Used in combination to treat Acid reflux Combination Product in combination with: Peppermint oil (DB11198), Magnesium trisilicate (DB09281) ••• ••• •••••• Used in combination to treat Acid regurgitation Combination Product in combination with: Calcium carbonate (DB06724), Alginic acid (DB13518), Simethicone (DB09512) ••• ••• •••••••••• Symptomatic treatment of Acid indigestion ••• ••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.
- Mechanism of action
Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.
- Absorption
Approximately 17-30% of the aluminum chloride formed is absorbed.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Not metabolized.
- Route of elimination
Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetaminophen Aluminum hydroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. Acetophenazine Aluminum hydroxide can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy. Alendronic acid The serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide. Alfacalcidol The serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol. Alimemazine Aluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Avoid foods rich in citrate. Citrate may increase the absorption of aluminum and has the potential to cause toxicity.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Algeldrate 03J11K103C 1330-44-5 SMYKVLBUSSNXMV-UHFFFAOYSA-K Almagate 568Z59H7ZJ 66827-12-1 MTEOMEWVDVPTNN-UHFFFAOYSA-E - Active Moieties
Name Kind UNII CAS InChI Key Aluminum cation ionic 3XHB1D032B 22537-23-1 REDXJYDRNCIFBQ-UHFFFAOYSA-N - International/Other Brands
- Alu-Cap (3M) / Amphojel (Wyeth)
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image ACTAL TABLET 216 mg Tablet 216 mg Oral A. MENARINI SINGAPORE PTE. LTD. 1989-06-30 Not applicable Singapore 
Alternagel Liquid 600 mg/5mL Oral Mc Neil Consumer Pharmaceuticals Co. 1990-01-01 2012-08-31 US 
Alu-tab Tab 600mg Tablet 600 mg / tab Oral 3 M Pharmaceuticals, A Division Of 3 M Canada Company 1993-12-31 2001-08-01 Canada 
ALU-TAB TABLET 600 MG Tablet Oral iNova Pharmaceuticals (Singapore) Pte Ltd (incorporated In Singapore) Malaysia Branch 2020-09-08 Not applicable Malaysia 
ALU-TAB TABLET 600 mg Tablet, film coated 600 mg Oral INOVA PHARMACEUTICALS (SINGAPORE) PTE. LIMITED 1989-05-22 Not applicable Singapore - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image ACED FULL SUSPENSION Aluminum hydroxide (4 g) + Magnesium hydroxide (4 g) + Simethicone (400 mg) Suspension Oral COASPHARMA S.A.S. 2018-06-12 Not applicable Colombia 
ACI-BIOGEL® SUSPENSION Aluminum hydroxide (4 g) + Magnesium hydroxide (4 g) + Simethicone (0.4 g) Suspension Oral EUROFARMA COLOMBIA S.A.S 2006-11-10 Not applicable Colombia Acid Gone Antacid Aluminum hydroxide (95 mg/15mL) + Magnesium carbonate (358 mg/15mL) Liquid Oral Major 2004-12-30 Not applicable US Acid Gone Antacid Extra Strength Aluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1) Tablet, chewable Oral Major Pharmaceuticals 2014-06-06 Not applicable US Acid Gone Antacid Extra Strength Aluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1) Tablet, chewable Oral Avera McKennan Hospital 2015-07-09 2017-05-24 US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AHC Premium Intense Contour Balm Aluminum hydroxide (0.45 g/50mL) + Adenosine (0.02 g/50mL) + Aluminium tristearate (0.04 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 CST) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Talc (2.05 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (0.96 g/50mL) Cream Topical Carver Korea Co.,Ltd. 2014-01-15 2017-11-22 US FIRST Mouthwash BLM Aluminum hydroxide (3.15 g/236mL) + Dimethicone 410 (0.315 g/236mL) + Diphenhydramine hydrochloride (.2 g/.2g) + Lidocaine hydrochloride (1.6 g/1.6g) + Magnesium hydroxide (3.15 g/236mL) Kit Oral CutisPharma, Inc. 2004-11-01 Not applicable US Medi Hydro DP BB Cream Aluminum hydroxide (0.07 mg/100mL) + Adenosine (0.00004 mg/100mL) + Nicotinamide (0.02 mg/100mL) + Stearic acid (0.05 mg/100mL) + Titanium dioxide (0.05 mg/100mL) Cream Topical Mbg Inc (Korea Institute of Science Development) 2017-08-08 2018-08-08 US
Categories
- ATC Codes
- A02AB02 — Algeldrate
- A02AB — Aluminium compounds
- A02A — ANTACIDS
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- A02AB — Aluminium compounds
- A02A — ANTACIDS
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Adjuvants, Immunologic
- Alimentary Tract and Metabolism
- Alkalies
- Aluminium Compounds
- Aluminum and magnesium containing antacids
- Anions
- Antacids
- Antacids and Adsorbents
- Carbon Compounds, Inorganic
- Carbonic Acid
- Drugs for Acid Related Disorders
- Electrolytes
- Gastric Acid Lowering Agents
- Gastrointestinal Agents
- Hydroxides
- Immunologic Factors
- Ions
- Metal cations
- Metal divalent cations
- Miscellaneous Local Anti-infectives
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Post-transition metal oxoanionic compounds
- Sub Class
- Post-transition metal hydroxides
- Direct Parent
- Post-transition metal hydroxides
- Alternative Parents
- Post-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
- Substituents
- Inorganic hydride / Inorganic oxide / Inorganic post-transition metal salt / Inorganic salt / Post-transition metal hydroxide
- Molecular Framework
- Not Available
- External Descriptors
- aluminium hydroxides (CHEBI:33130)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5QB0T2IUN0
- CAS number
- 21645-51-2
- InChI Key
- WNROFYMDJYEPJX-UHFFFAOYSA-K
- InChI
- InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
- IUPAC Name
- aluminium(3+) trihydroxide
- SMILES
- [OH-].[OH-].[OH-].[Al+3]
References
- Synthesis Reference
Richard H. Goheen, William A. Nigro, Paul J. The, "Process for producing aluminum hydroxide of improved whiteness." U.S. Patent US4915930, issued November, 1933.
US4915930- General References
- Not Available
- External Links
- KEGG Compound
- C13391
- PubChem Compound
- 10176082
- PubChem Substance
- 175427087
- ChemSpider
- 8351587
- 81948
- ChEBI
- 33130
- ChEMBL
- CHEMBL1200706
- Wikipedia
- Aluminum_hydroxide
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Prevention Vaccine Responsiveness During Allergy De-sensitization Treatment / Vaccine Responsiveness in Allergy 1 4 Completed Treatment Dyspepsia 1 4 Completed Treatment Gastro-esophageal Reflux Disease (GERD) 1 4 Unknown Status Treatment Esophageal Cancer / Gastric Cancer 1 3 Completed Prevention Aneurysmal Subarachnoid Hemorrhages (aSAH) / Cerebral Ischemia / Cerebral Vasospasm / Delayed Cerebral Ischemia / Subarachnoid Hemorrhage 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Intra-articular; Oral Tablet; tablet, chewable Oral Tablet Oral 216 mg Tablet Oral 120 mg Tablet Oral 300 mg Tablet Oral Tablet, chewable Oral Liquid Oral Tablet, chewable Oral Tablet Oral 500.000 mg Liquid Oral 600 mg/5mL Tablet Oral 600 mg / tab Tablet, film coated Oral 600 mg Gel Oral 320 mg/5mL Liquid Oral 320 mg/5mL Tablet Ointment Topical 0.275 g/100g Ointment Topical 1.356 g/113g Ointment Topical 0.275 % Ointment Topical 2 g/100g Capsule, liquid filled Oral Tablet, chewable Buccal 470 mg Solution Oral Powder Oral Kit Oral Suspension Oral 6.3 g Suspension Oral 50 mg/ml Suspension Oral 6 g Tablet, chewable Buccal Gel Buccal; Oral Granule Oral Liquid Topical Suspension Powder, for suspension Oral Suspension Oral 3.5 % Tablet, chewable Oral 200 MG Tablet Oral 200.000 mg Injection, powder, for suspension Intramuscular Suspension Oral Suspension Oral 400 mg/5ml Tablet, chewable Oral 234 mg Suspension Oral 6.15 g Ointment Topical Tablet Oral Gel Oral Cream Topical Suspension Oral 57.97 g Tablet Oral 200 mg Tablet Oral 250 mg Powder Tablet Oral 500 mg Tablet Oral 300 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 1.45 Chemaxon pKa (Strongest Acidic) 4.07 Chemaxon Physiological Charge 3 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 0 m3·mol-1 Chemaxon Polarizability 1.78 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.5922 Blood Brain Barrier + 0.8181 Caco-2 permeable - 0.5094 P-glycoprotein substrate Non-substrate 0.8274 P-glycoprotein inhibitor I Non-inhibitor 0.9892 P-glycoprotein inhibitor II Non-inhibitor 0.9783 Renal organic cation transporter Non-inhibitor 0.9433 CYP450 2C9 substrate Non-substrate 0.8282 CYP450 2D6 substrate Non-substrate 0.9 CYP450 3A4 substrate Non-substrate 0.8206 CYP450 1A2 substrate Non-inhibitor 0.9291 CYP450 2C9 inhibitor Non-inhibitor 0.9148 CYP450 2D6 inhibitor Non-inhibitor 0.9584 CYP450 2C19 inhibitor Non-inhibitor 0.9447 CYP450 3A4 inhibitor Non-inhibitor 0.9672 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9578 Ames test Non AMES toxic 0.8393 Carcinogenicity Carcinogens 0.5918 Biodegradation Ready biodegradable 0.81 Rat acute toxicity 1.7247 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9592 hERG inhibition (predictor II) Non-inhibitor 0.9742
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at August 09, 2010 17:11 / Updated at February 20, 2024 23:55